SCHEMBL15480477

SCHEMBL15480477

CCc1ccc2cc(COC(=O)Nc3ccc(C(=O)NO)cc3)ccc2c1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 6/20 0.78
HDAC6 Q9UBN7 4/20 0.78
HDAC2 Q92769 3/20 0.78
HDAC3 O15379 2/20 0.78
HDAC4 P56524 2/20 0.78
HDAC7 Q8WUI4 2/20 0.78
HDAC10 Q969S8 2/20 0.78
HDAC11 Q96DB2 2/20 0.78
HDAC8 Q9BY41 2/20 0.78
HDAC9 Q9UKV0 2/20 0.78
HDAC5 Q9UQL6 2/20 0.78
NCOR2 Q9Y618 1/20 0.78
NAMPT P43490 1/20 0.49
F2 P00734 1/20 0.47
PLG P00747 1/20 0.47
PLAU P00749 1/20 0.47
PLAT P00750 1/20 0.47
KLKB1 P03952 1/20 0.47
PRSS1 P07477 1/20 0.47
PTGDR2 Q9Y5Y4 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15480475 0.89 HDAC1 (0.72) HDAC1HDAC6HDAC2HDAC3HDAC4
SCHEMBL9943838 0.88 HDAC6 (0.71) HDAC1HDAC6HDAC2HDAC3HDAC4
SCHEMBL14789603 0.88 HDAC3 (0.60) HDAC1HDAC6HDAC2HDAC3HDAC4
Givinostat SCHEMBL29361624 0.88 HDAC6 (1.00) HDAC1HDAC6HDAC2HDAC3HDAC4
Givinostat SCHEMBL1555814 0.88 HDAC6 (1.00) HDAC1HDAC6HDAC2HDAC3HDAC4
Givinostat SCHEMBL30527230 0.87 HDAC6 (0.98) HDAC1HDAC6HDAC2HDAC3HDAC4
Givinostat SCHEMBL1554636 0.87 HDAC6 (0.98) HDAC1HDAC6HDAC2HDAC3HDAC4
Givinostat SCHEMBL2468061 0.86 HDAC6 (0.96) HDAC1HDAC6HDAC2HDAC3HDAC4
SCHEMBL14789609 0.83 HDAC3 (0.57) HDAC1HDAC6HDAC2HDAC3HDAC4
SCHEMBL15480480 0.79 HDAC1 (0.66) HDAC1HDAC6HDAC2HDAC3HDAC4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC6 10/4885HDAC2 3/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC6 10/4885HDAC2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.